COVID-19 and MS disease-modifying therapies.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
16
04
2020
accepted:
26
04
2020
entrez:
17
5
2020
pubmed:
18
5
2020
medline:
21
5
2020
Statut:
epublish
Résumé
To address concerns regarding the effect of MS disease-modifying therapies (DMTs) on the expression of coronavirus 2019 (COVID-19). Review of the current state of knowledge regarding the viral etiology of COVID-19, mechanisms of injury by SARS-CoV-2 infection, and the effect of individual DMTs on the risk of infection and COVID-19 disease expression. Although data are limited, MS DMTs do not obviously increase the risk of acquiring symptomatic SARS-CoV-2 infection. The severe morbidity and mortality of SARS-CoV-2 appear to be largely the consequence of an overly robust immune response rather than the consequence of unchecked viral replication. The effects of specific MS DMTs on the immune response that may increase the risk of impaired viral clearance and their potential counterbalancing beneficial effects on the development of COVID-19-associated acute respiratory distress syndrome are reviewed. Although there is currently insufficient real-world experience to definitively answer the question of the effect of a specific MS DMT on COVID-19, registries presently in nascent form should provide these answers. This review provides an approach to addressing these concerns while the data are being accumulated. Early insights suggest that the risk of infection and associated morbidity of COVID-19 in this population is little different than that of the population at large.
Identifiants
pubmed: 32414755
pii: 7/4/e761
doi: 10.1212/NXI.0000000000000761
pmc: PMC7238896
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI144288
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Drug Saf. 2004;27(10):745-56
pubmed: 15350158
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Curr Neurol Neurosci Rep. 2017 Sep 22;17(11):88
pubmed: 28940162
Ther Adv Neurol Disord. 2015 Sep;8(5):233-8
pubmed: 26557898
Mult Scler. 2002 May;8(3):237-42
pubmed: 12120696
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Neurology. 2019 Mar 5;92(10):e1029-e1040
pubmed: 30770430
J Neurol. 2014 Jun;261(6):1170-7
pubmed: 24728334
J Neuroimmunol. 1999 Sep 1;99(1):131-41
pubmed: 10496186
Ann Neurol. 1994;36 Suppl:S25-8
pubmed: 8017885
J Immunol. 2004 Jun 1;172(11):7144-53
pubmed: 15153538
JAMA Neurol. 2020 Feb 1;77(2):184-191
pubmed: 31589278
J Neurovirol. 2012 Oct;18(5):411-5
pubmed: 22585288
Brain Behav. 2017 Mar 14;7(4):e00671
pubmed: 28413713
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Neuroepidemiology. 2008;30(1):13-9
pubmed: 18204292
PLoS Pathog. 2008 Dec;4(12):e1000240
pubmed: 19079579
NeuroRehabilitation. 2004;19(1):55-67
pubmed: 14988588
J Neuroimmunol. 2015 May 15;282:118-22
pubmed: 25903738
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):147-157
pubmed: 32391658
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Annu Rev Biochem. 1987;56:727-77
pubmed: 2441659
J Neurovirol. 2007;13(1):73-7
pubmed: 17454451
Thromb Haemost. 2008 Mar;99(3):494-501
pubmed: 18327397
mBio. 2018 Oct 9;9(5):
pubmed: 30301856
J Pathol. 2015 Jan;235(2):185-95
pubmed: 25270030
Laryngoscope. 2020 Jul;130(7):1787
pubmed: 32237238
Nat Med. 2007 Aug;13(8):935-43
pubmed: 17676050
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
J Infect. 2020 Apr;80(4):401-406
pubmed: 32112886
J Cereb Blood Flow Metab. 2003 Sep;23(9):1060-9
pubmed: 12973022
J Clin Invest. 2000 Apr;105(7):967-76
pubmed: 10749576
J Neuroimmunol. 2000 Mar 1;103(2):202-10
pubmed: 10696916